Results 51 to 60 of about 1,009 (151)

Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV

Advanced Science, Volume 13, Issue 9, 13 February 2026.
This study finds that CD8⁺ TSCM cells exhibit superior self‐renewal, differentiation, and antiviral activity. Transcriptome and epigenome analyses highlight MAPK cascade regulation in TSCM cells. In vivo, virus‐specific TSCM cells show enhanced persistence and tumor protection.
Xun‐Hong Cao, Xu‐Ying Pei, Yuan‐Yuan Zhang, Juan Xie, Jing‐Wei Tu, Zhuo‐Jun Liu, Yi‐Yang Ding, Chen‐Hua Yan, Yu‐Hong Chen, Yu Wang, Lan‐Ping Xu, Xiao‐Hui Zhang, Xiao‐Jun Huang, Xiang‐Yu Zhao   +13 more
wiley   +1 more source

Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report

Clinical Pathology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive neoplastic process of precursor plasmacytoid dendritic cells. The diagnostic evaluation of this heterogenous entity is challenging, requiring a comprehensive approach of ...
Jasper X Zheng, Elham Vali Betts, Denis M Dwyre, Jong H Chung, Ananya Datta Mitra   +4 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm and cerebral toxoplasmosis: a case report

BMC Neurology, 2022
Background The present case contributes to the limited literature on central nervous system involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Anna Maria Florescu, Anne Louise Tølbøll Sørensen, Henrik Vedel Nielsen, Daniel Tolnai, Lene Dissing Sjö, Katja Lohmann Larsen, Mohammad Al-Mahdi Al-Karagholi   +6 more
doaj   +1 more source

Covalent Organic Frameworks for Photocatalysis

Advanced Materials, Volume 37, Issue 52, December 29, 2025.
This review provides an overview of recent advances in covalent organic frameworks (COFs) for photocatalysis, focusing on sustainable energy applications like water splitting, hydrogen peroxide generation, and CO2 and N2 reduction. It discusses design principles, structure‐function relationships, challenges in COF photocatalysis, and strategies to ...
Bikash Mishra, Akhtar Alam, Avanti Chakraborty, Bidhan Kumbhakar, Samrat Ghosh, Pradip Pachfule, Arne Thomas   +6 more
wiley   +1 more source

18F-FDG PET/CT findings in a patient with blastic plasmacytoid dendritic cell neoplasm and post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation: a case report

Frontiers in Medicine, 2023
BackgroundBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematopoietic malignancy, which originating from precursors of plasmacytoid dendritic cells.
Jinzhi Chen, Xi Zhang, Linlin Ma, Yuan Gao, Zhanli Fu, Meng Liu   +5 more
doaj   +1 more source

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Nature Communications, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy derived from the precursors of plasmacytoid dendritic cells.
Tianyu Cai, Agnès Gouble, Kathryn L. Black, Anna Skwarska, Ammar S. Naqvi, Deanne Taylor, Ming Zhao, Qi Yuan, Mayumi Sugita, Qi Zhang, Roman Galetto, Stéphanie Filipe, Antonio Cavazos, Lina Han, Vinitha Kuruvilla, Helen Ma, Connie Weng, Chang-Gong Liu, Xiuping Liu, Sergej Konoplev, Jun Gu, Guilin Tang, Xiaoping Su, Gheath Al-Atrash, Stefan Ciurea, Sattva S. Neelapu, Andrew A. Lane, Hagop Kantarjian, Monica L. Guzman, Naveen Pemmaraju, Julianne Smith, Andrei Thomas-Tikhonenko, Marina Konopleva   +32 more
doaj   +1 more source

Radiation Therapy for Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report and Review of the Literature

Current Oncology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from plasmacytoid dendritic cells. It commonly presents as cutaneous lesions.
Masashi Taka, Shinichiro Toyoshima, Shigeyuki Takamatsu, Satoshi Kobayashi   +3 more
doaj   +1 more source

Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm

Journal of Investigative Medicine High Impact Case Reports, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed
Prashanth Ashok Kumar MBBS, Mulham Ombada MBBS, Gayatri Pemmasani MBBS, Ajay Tambe MBBS, Katalin Banki MD, Teresa Gentile MD, PhD   +5 more
doaj   +1 more source

Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview

Hematology Reports, 2023
Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCNs) are a rare, highly aggressive hematological malignant neoplasm that primarily involve the skin, bone marrow, lymph nodes and even extra-nodal sites. The rarity and relative poor description of cases in the literature make it necessary to review and further studies that deeply investigate this ...
Gerardo Cazzato, Marialessandra Capuzzolo, Emilio Bellitti, Giovanni De Biasi, Anna Colagrande, Katia Mangialardi, Francesco Gaudio, Giuseppe Ingravallo   +7 more
openaire   +3 more sources

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia

British Journal of Haematology, Volume 207, Issue 4, Page 1178-1191, October 2025.
Summary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Alexandra Dreyzin, Noa G. Holtzman, Challice L. Bonifant   +2 more
wiley   +1 more source